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Abstract
The innate immune system must recognize and rapidly respond to microbial pathogens, providing 
a first line of host defense. This is accomplished through an array of pattern recognition receptors 
(PRRs) which reside in specific subcellular compartments and can bind pathogen-associated 
molecular patterns (PAMPs). PRRs also recognize self-molecules that are released after cell 
damage or death known as danger-associated molecular patterns (DAMPs), which can be actively 
transported across cell membranes. The activation of PRRs leads to host defense pathways in 
infectious diseases but can also contribute to tissue injury in autoimmune diseases. The 
identification of these pathways has provided new insight into mechanisms of vaccination and 
holds promise for developing better vaccines. Finally, the identification of PRRs, their ligands and 
signaling pathways provides an opportunity for developing new immunotherapeutic approaches to 
skin conditions in which activation of the innate immune response contributes to disease 
pathogenesis.
The current model of innate immunity derives from the seminal observations of Elie 
Metchnikoff (Modlin and Cheng, 2004). By studying starfish larvae, he realized that mobile 
cells might serve in the host's defense against microbial pathogens. In 1884, Metchnikoff 
demonstrated that cells of the water-flea Daphnia, which he termed phagocytes, were 
attracted to and engulfed spores of a yeast-like fungus (Metschnikoff, 1884). He wrote that 
“the spores which reached the body cavity are attacked by blood cells, and- probably 
through some sort of secretion- are killed and destroyed”. Thus Metchnikoff had described 
the direct functions of the innate immune system: 1) rapid detection of microbes, 2) 
phagocytosis and 3) antimicrobial activity. The phagocytic function of the innate immune 
system also contributes to tissue homeostasis, for example in clearing toxic metabolites, 
dead cells and debris, as well as in regulating wound healing.
The contemporary view of the innate immune system is based on Metchnikoff's model. The 
direct functions of the innate immune system provide a rapid first line of defense against 
microbial pathogens. However, the innate immune system by itself may not be sufficient to 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Address correspondence to: Robert L. Modlin, M.D., UCLA Division of Dermatology, 52-121 CHS, 10833 Le Conte Avenue, Los 
Angeles, CA 90095, Tel: (310) 825-6214, Fax: (310) 206-9878, rmodlin@mednet.ucla.edu. 
HHS Public Access
Author manuscript
J Invest Dermatol. Author manuscript; available in PMC 2012 September 01.
Published in final edited form as:
J Invest Dermatol. 2012 March ; 132(3 0 2): 882–886. doi:10.1038/jid.2011.373.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
eliminate many microbial pathogens. Ultimately, the adaptive immune system, composed of 
T and B cell, and although slower to develop than the innate immune response, clears the 
microbial invader. The innate and adaptive immune responses are linked, as the innate 
immune response has an indirect function in host immunity, an instructive role in 
stimulating adaptive T and B cell responses. Conversely, the adaptive immune response can 
activate cells of the innate immune system.
It would take over 100 years after Metchnikoff's description of innate immunity for 
immunologists to discover the mechanisms by which cells of the innate immune system 
could rapidly recognize microbial invaders and subsequently destroy them. Improvements in 
light microscopy provided Metchnikoff with the necessary scientific tool to discover innate 
immunity. In 1868, the microscope allowed Paul Langerhans to visualize cells with a 
dendritic morphology in the epidermis (Langerhans, 1868). These cells, known as 
“Langerhans cells”, are now known to be a key part of the skin immune system.
In 1873, Gerhard Armauer Hansen used microscopy to discover the first human pathogen, 
Mycobacterium leprae, the cause of leprosy (Hansen, 1874). Fehleisen identified and 
cultured Streptococcus pyogenes as the causative agent of erysipelas (Fehleisen, 1883). 
Around this time, several investigators noted that the occurrence of erysipelas in cancer 
patients sometimes resulted in the regression or remission of the tumor, including Busch 
(Busch, 1866), Fehleisen (Fehleisen, 1883) and the Russian writer and physician, Anton 
Chekov (Gresser, 1987). In addition, patients with various malignancies were inoculated 
with “erysipelas” and shrinkage of the tumor was noted (Fehleisen, 1883). William B. Coley 
continued these studies, and reported in 1891 that in patients with sarcoma, there was 
regression of the tumor upon contraction of erysipelas (Coley, 1891). Coley directly 
inoculated ten patients with various sarcomas with a bacterial culture derived from 
erysipelas lesions, as well as the toxins from these cultures, resulting in dramatic regression 
of some tumors (Coley, 1893). These “Coley's toxins” were a mixture of Streptococcus 
pyogenes and Serratia marcescens. Coley is frequently labeled as the “father of 
immunotherapy”, and the mechanism of such therapy involving activation of the innate 
immune system. It is also worth considering why a skin disease, erysipelas, was identified as 
a potential mechanism of augmenting anti-tumor immunity. Clearly the skin is readily 
observable and accessible, so it was more likely that an exact clinical diagnosis based on 
morphology could be made and that specimens could be readily obtained for microbiologic 
identification or immunotherapy. It is therefore no accident that some of the early 
breakthroughs in microbiology and immunotherapy came from the study of skin diseases 
such as leprosy and erysipelas.
As scientists were trying to improve vaccines, they noted that an intercurrent infection 
enhanced efficacy. Lewis and Loomis: “were led by an accidental occurrence to carry 
through an experiment designed to show whether a preexisting tuberculosis affected the 
production of antibody for an antigen unrelated to the tubercle bacillus. The result was 
definite, showing a decided increase in anti-sheep amboceptor production by tuberculous 
guinea pigs.”(Lewis and Loomis, 1924) They called this ability of tuberculosis infection to 
increase anti-sheep erythrocyte antibody production “allergic irritability”. In modern 
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immunology, we describe this as an adjuvant, an agent that when added to a vaccine would 
augment the immune response to the target antigen.
The term adjuvant, from a Latin word meaning ‘to help’, was coined in the 1920s by Gason 
Ramon, a veterinarian at the Pasteur Institute (Pollack, 2009). He found that horses 
immunized with diphtheria toxoid have a stronger response if they developed an abscess at 
the inoculation site, and that adjuvant activity was obtained by the addition of substances 
such as bread crumbs or tapioca to the vaccine (Ramon, 1925; Ramon, 1926). At the same 
time, aluminum salts were used to precipitate and purify toxins, as well as in immunization 
protocols. Importantly, the efficacy of a diphtheria toxoid vaccine was improved by the 
addition of alum (Glenny et al., 1926), which subsequently became a major adjuvant in 
vaccines against infections in humans. In 1956, Freund developed what would become the 
standard adjuvants for vaccines in animal studies (Freund, 1956). Freund's complete 
adjuvant utilizes inactivated mycobacteria as a component. Subsequently, the 
immunotherapeutic potential of the live mycobacterium BCG was explored in bladder 
cancer (Morales et al., 1976) and melanoma (Morton et al., 1970).
For over a century, immunologists used bacterial products in vaccines, with the knowledge 
that bacterial products had special properties that could be harnessed in preventing and 
treating disease, yet unaware of the mechanisms involved. Discovery of the molecular 
mechanisms of innate immunity and how adjuvants work would require over 100 years of 
scientific and technical progress in a variety of disciplines: cell biology, biochemistry, 
genetics and high speed computing. Innate immunity was ignored, but not forgotten; it was 
not understood, but it was induced as part of vaccines.
Charles Janeway advanced our thinking about the mammalian innate immune system by 
confronting what had been ignored, asking “Why do we need to use adjuvants” (Janeway, 
Jr., 1989). It was necessary to add adjuvants to vaccines in order to induce robust immune 
responses to antigen. Janeway called this “the immunologists dirty little secret” (Janeway, 
Jr., 1989). He further reasoned that the adaptive immune response required two signals for 
activation: ligation of the specific receptor on the surface of a T or B cell by the antigen, but 
also a second signal derived from another cell, the antigen presenting cell, later identified as 
costimulatory molecules (Janeway, Jr., 1989). Janeway hypothesized that the capacity of 
antigen presenting cells to elicit an adaptive response was induced by a distinctive 
recognition event involving evolutionarily primitive receptors, enhancing antigen 
presentation function. Janeway's group gained insight from the study of innate immunity in 
Drosophila, implicating the Toll protein in recognition of foreign microbes and in activating 
host defense. They discovered that triggering of a human homolog of the Drosophila Toll 
protein, Toll-like receptor 4 (TLR4), on innate immune cells, upregulated costimulatory 
molecule expression and cytokine release required for T cell activation (Medzhitov et al., 
1997). These data indicated that activation of TLRs on cells of the innate immune system 
could instruct the adaptive immune response.
The discovery that TLRs could trigger innate immune responses raised the possibility that 
TLRs mediated recognition of microbial ligands. It was known that the innate immune 
system detected microbes using pattern recognition receptors, which recognized biochemical 
Modlin Page 3
J Invest Dermatol. Author manuscript; available in PMC 2012 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
patterns expressed by groups of microbes, termed pathogen-associated molecular patterns 
(PAMPs). Yet up until that time, many of the identified pattern recognition receptors (PRRs) 
had no known intracellular signaling capacity. TLRs were logical candidates- being 
transmembrane proteins containing repeated leucine-rich motifs in their extracellular 
portions, similar to other pattern recognition proteins and containing a cytoplasmic portion 
which is homologous to the IL-1 receptor, and hence could trigger intracellular signaling 
pathways. Beutler's group used a genetics approach to identify TLR4 as the receptor for 
LPS, providing a mechanism for innate immune recognition of Gram negative bacteria 
(Poltorak et al., 1998). Our lab discovered that microbial lipoproteins trigger host responses 
via TLR2, providing a mechanism for innate immune recognition of both Gram positive and 
Gram negative organisms. TLR2/6 heterodimers mediate the response to diacylated 
lipoproteins, whereas TLR2/1 heterodimers recognize triacylated lipoproteins (Brightbill et 
al., 1999). For recognition of bacteria, the TLR system is redundant: TLR9 is activated by 
unmethylated DNA sequences (CpG dinucleotides) found in bacterial DNA (Hemmi et al., 
2000) and TLR5 activated by bacterial flagellin (Hayashi et al., 2001). Specific TLRs are 
involved in viral recognition: TLR3 is activated by viral derived double-stranded RNA 
(Alexopoulou et al., 2001) and TLR7 and TLR8 by viral derived single stranded RNA 
(Diebold et al., 2004) (Figure 1).
The identification of TLR ligands made possible experiments to investigate the functional 
role of TLRs in the innate immune response. In Metchnikoff's model of innate immunity, 
recognition of the foreign invader was followed by phagocytosis. It is required not only for 
physical destruction of the pathogen, but also allows for microbial antigen presentation to T 
cells in the context of MHC molecules. TLRs can regulate phagocytosis either through 
enhancing endosomal fusion with the lysosomal compartment (Blander and Medzhitov, 
2004) or through induction of a phagocytic gene program including multiple scavenger 
receptors (Doyle et al., 2004).
TLRs also fulfill the final step of Metchnikoff's innate immunity- the induction of direct 
antimicrobial activity. Activation of TLRs on monocytes triggers an antimicrobial activity 
against intracellular bacteria such as M. tuberculosis, which in mice is NO dependent and 
human NO independent (Thoma-Uszynski et al., 2001). In human monocytes, activation of 
TLRs induced an antimicrobial activity against M. tuberculosis that was vitamin D 
dependent (Liu et al., 2006). This pathway involved induction of IL-15, leading to induction 
of 25-hydroxyvitamin D3-1α-hydroxylase (CYP27b1), which converts 25D into the active 
1,25D form and upregulation/ activation of the vitamin D receptor (VDR) (Krutzik et al., 
2008). The activation of the VDR triggered expression of the antimicrobial peptide 
cathelicidin (Liu et al., 2006). Furthermore, the induction of IL-1β and the VDR was 
required for upregulation of DEFB4 (Liu et al., 2009). The TLR-induced, vitamin D-
dependent antimicrobial pathway required induction of the antimicrobial peptides 
cathelicidin and DEFB4 (Liu et al., 2007). In addition, activation of TLR3, TLR4, TLR7, 
TLR8 and TLR9 leads to induction of antiviral activity that is dependent on Type I 
interferon secretion and involves specific signaling pathways (Doyle et al., 2002).
The specific subcellular location of TLRs allows the detection of microbes in distinct 
compartments. TLR3, 7, 8 and 9 are located in endosomes, facilitating recognition of RNA 
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and DNA from microbial pathogens that reside in the endocytic pathway. In contrast, TLR1, 
2, 4, 5 and 6 are located on the cell surface, providing the innate immune system with the 
ability to recognize extracellular pathogens or PAMPs released from intracellular pathogens 
into the extracellular space. Other PRRs are located in the cytoplasm, including the NLRs 
(NOD [Nucleotide-binding oligomerization domain]-like receptors), which share homology 
to TLRs in containing leucine rich repeats. NOD1 and NOD2 recognize components of 
bacterial cells walls; specifically NOD1 recognizes D-glutamyl-meso-diaminopimelic acid 
(Girardin et al., 2003a) and NOD2 senses muramyl dipeptide (Girardin et al., 2003b; Inohara 
et al., 2003; Yang et al., 2007). Stimulation of NLRs can activate a protein complex known 
as the inflammasome, which by recruitment of caspase-1, leads to the proteolytic cleavage 
and activation of IL-1β and other cytokines (Martinon et al., 2009).
The discovery of NLRs has provided new insight into how vaccine adjuvants work. It is 
tempting to speculate that the utility of BCG as an adjuvant is related to its ability to activate 
NOD2. A key component of mycobacterial cell walls that confers adjuvant activity is the 
NOD2 agonist, muramyl dipeptide (Adam et al., 1974; Ellouz et al., 1974). Muramyl 
dipeptide has been shown to be an effective adjuvant for inducing both B cell (Specter et al., 
1978) and T cell (Sugimoto et al., 1978) responses. A muramyl dipeptide derivative has 
been explored as a possible immunotherapeutic agent in the treatment of patients with 
osteosarcoma (Kleinerman et al., 1992). Human monocytes with a functional defect in 
NOD2 were found to have an 80% reduction in cytokine response to M. tuberculosis 
(Ferwerda et al., 2005). The vaccine adjuvant alum also activates the NLR family, 
specifically the inflammasome component Nalp3 (Eisenbarth et al., 2008).
In addition to recognizing pathogen associated molecular patterns (PAMPs) derived from 
microbes, pattern recognition receptors of the innate immune system have been able to 
recognize danger associated molecular patterns (DAMPs) derived from injured or damaged 
host cells (Martinon et al., 2006). Some DAMPs include ATP, heparin sulfate, HMGB1 and 
S100 proteins. The ability of the innate immune response to respond to DAMPs contributes 
to tissue homeostasis and repair, but the resulting inflammatory response can result in 
autoimmune disease. For example, the recognition of uric acid crystals by the NALP3 
inflammasome contributes to the pathogenesis of gout (Martinon et al., 2006). Of relevance 
to skin disease, the inflammasome is activated in keratinocytes by UVB, as well as chemical 
agents that induce irritant and contact dermatitis (Watanabe et al., 2007).
The location of pattern recognition receptors of the innate immune system in distinct 
subcellular compartments facilitates detection of microbial pathogens. At the same time, the 
location of these receptors prevents activation by self-molecules which share homology to 
microbial ligands, but do not normally access these locations. However, when self-
molecules gain access to these compartments, autoimmune disease can be triggered (Davis 
et al., 2011; Martinon et al., 2009). The innate system participates in inflammation 
associated carcinogenesis (Davis et al., 2011). In the case of cell damage or death, the 
upregulation and release of DAMPs provides one mechanism by which self-molecules gain 
access to innate immune pattern recognition receptors. A second mechanism involves the 
transport of self-molecules across membranes into compartments containing specific pattern 
recognition receptors.
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Michel Gilliet's group has elucidated a transport mechanism by which self-DNA is 
trafficked from an extracellular location directly to endosomes resulting in activation of the 
innate immune system via TLR9 (Lande et al., 2007). This transportation pathway may 
contribute to the pathogenesis of psoriasis. First, the release of DNA from damaged cells 
complexes with the antimicrobial peptide cathelicidin (aka LL-37), known to be increased in 
psoriasis. These DNA-cathelicidin complexes can then be transported across cell membranes 
and then delivered into endosomes of plasmacytoid dendritic cells, with subsequent 
activation of TLR9 and release of type I IFNs known to trigger autoimmune T cell 
responses. Cathelicidin and anti-DNA/RNA antibodies can transport both DNA and RNA 
into endosomes where they activate relevant TLRs and contribute to the pathogenesis of 
autoimmune disease. These transportation pathways may be beneficial to the host in 
combating microbial infection, but can also contribute to tissue damage.
There are a wide range of inflammatory and infectious skin diseases in which activation 
and/or dysregulation of pattern recognition receptor signaling contributes to pathogenesis 
(Lai and Gallo, 2008; Terhorst et al., 2010). The discovery of mammalian pattern 
recognition receptors and their biologic roles has also provided an exciting new opportunity 
to develop new pharmacologic agents. We have learned from the study of innate immunity 
that the drug imiquimod, used to treat viral warts and actinic keratoses, triggers TLR7 to 
induce a pro-inflammatory response (Hemmi et al., 2002). It is tempting to speculate that 
other TLR and NLR agonists may also serve as immunotherapeutic agents and/or adjuvants 
for a new generation of vaccines. However, there are circumstances in which blocking 
innate immune responses may be beneficial, raising the possibility that antagonists hold 
promise for a new class of anti-inflammatory agents. Metchnikoff's initial studies of the 
innate immune systems of starfish and the water-flea have enabled us to develop insight into 
the human innate immune system and provide the potential to intervene in human disease.
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Figure 1. Innate immune pathways of host defense in infection
Innate immune receptors reside in specific subcellular compartments, including cell surface, 
cytoplasmic and endocytic, providing the opportunity to recognize distinct microbial 
ligands. Some of the key pattern recognition receptors (PRRs) involved in skin disease are 
shown, along with some of their microbial ligands, pathogen-associated molecular patterns 
(PAMPs). Included are various TLRs (Toll-like receptors), NLRs (NOD-like receptors), 
RLRs (RIG-I like receptors). The activation of the innate immune system leads host immune 
responses that contribute to skin disease including the differentiation of monocytes into 
macrophage subsets, antimicrobial activity, dendritic cell differentiation and T cell 
differentiation. The key molecules involved in each process are shown.
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